For someone with a retinal disease such as retinitis pigmentosa or macular degeneration, their vision loss is caused by photoreceptor degeneration. Photoreceptors are the retinal cells that capture light and convert it into electrical signals, which are sent back to the brain where they are used to create the images we see. Continue Reading…
Get the inside scoop on this year’s top research advances and what’s next in retinal disease science by watching VISIONS 2018 LIVE!
We will be streaming several of our annual VISIONS conference sessions live on Friday, June 22 and Saturday, June 23. The sessions will be live streamed here on our blog, and our national Facebook as well.
Here’s the full schedule of live sessions:
Friday, June 22, 2018
9:00 a.m. PDT – 10:15 a.m. PDT– Opening Session: Mission Possible! The Year’s Top Advances and What’s Next in Retinal Disease Science
Horama, a French biotech developing gene therapies for rare eye diseases, was established in 2014 as a spin-off of INSERM, France’s public scientific and technology institute. Today, the company has three gene-therapy development programs underway for rare inherited retinal diseases, targeting people with mutations in the genes PDE6B, RPE65, and RLBP1. Continue Reading…
Dr. Christopher Brittain, Genentech medical director, discusses his company’s port delivery system, a tiny capsule implanted into the eye, for delivery of Lucentis® over a period of a few months. The device is currently in a Phase 2 clinical trial.
The image on the right shows the port implanted into an eye.
After presenting a poster on a new mutation in the RP gene KIF3B at the ARVO meeting in Honolulu, FFB-funded geneticist Dr. Stephen Daiger discusses the progress that’s been made in genetic testing for people with inherited retinal conditions.
Several research studies have suggested that the Mediterranean diet (MeDi) – which is rich in fruits, vegetables, legumes, cereals, and fish – may be good for your health, including lowering your risk of an early visit from the grim reaper.
At the annual ARVO research conference in Honolulu, I had an opportunity to talk with FFB-funded researcher Shannon Boye, PhD, University of Florida, about her advancement of gene therapy for Leber congenital amaurosis (GUCY2D mutations) toward a clinical trial.
Medical Disclaimer:The information contained on the Foundation Fighting Blindness web site and other online properties including Eye on the Cure is provided for your general information only. The Foundation does not give medical advice or engage in the practice of medicine. Physicians differ in their approach to incorporating research results into their clinical practice. You should always consult with and be guided by your Physician’s advice when considering treatment based on research results.
All information and content on this web site are protected by copyright.